Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialDNA 또는 NYVAC 벡터(HVTN 096)가 있는 외피 단백질을 포함하는 다가 HIV 백신의 안전성 및 면역원성: 1b상, 이중 맹검, 위약 대조 시험Article Published on 2019-10-072022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] active treatment Administered administration adverse event allergy antibodies antibody Antibody Response Antibody responses antibody-dependent cell-mediated cytotoxicity approach assigned binding binding antibody boost Cell-mediated cytotoxicity Combination component computer-generated Coverage cranial cytotoxicity died DNA dose doses double-blind early administration effective Efficacy enrolled envelope protein epitope finding followed by foundation funding glycoprotein gp120 healthy healthy volunteer healthy volunteers HIV infection HIV vaccine IgG IgG response IgG responses immunogenicity individual Infection Infectious diseases injection Lymphadenopathy marker measure Melinda Gate Melinda Gates motor vehicle Neutralising Antibodies outcome participant Participants Placebo placebo group placebo-controlled placebo-controlled trial Primary outcomes priming product Protein purified random Randomly reactogenicity regimen Registered responses risk Safety screened Serious Adverse Event Serious Adverse Events Switzerland the placebo group the vaccine trauma Treatment treatment group treatment groups Trial trials vaccination vaccination schedule Vaccinations Vaccine vector Volunteer [DOI] 10.1016/S2352-3018(19)30262-0 PMC 바로가기 [Article Type] Article
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial저위험 HIV 감염되지 않은 남아프리카 성인을 대상으로 한 아형 C ALVAC-HIV 및 2가 아형 C gp120/MF59 HIV-1 백신: 1/2상 시험Article Published on 2018-06-182022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] 95% CI added adjuvant advancement African allergy Antigen assigned binding antibody CD4+ T-cell changed circulating clinical Community component computer-generated Critical double-blind trial Efficacy enrolled exceeded Express finding foundation funding glycoprotein gp120 HIV HIV infection HIV vaccine HIV-1 HIV-uninfected IgG IgG response immune response immune responses immunogenicity IMPROVE Infectious disease Infectious diseases Intramuscular injection investigators Melinda Gate Melinda Gates MF59 network NIAID outcome participant per-protocol per-protocol analysis Placebo predicted Primary outcomes Protein provided random randomisation randomised controlled Randomly recipient regimen Registered registry reported Research responders response risk significantly higher South South Africa strain Strains subtype T-cell Response tested the vaccine threshold titre Trial vaccination Vaccine Vaccine development was done [DOI] 10.1016/S2352-3018(18)30071-7 PMC 바로가기 [Article Type] Article
Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial아프리카에서 HIV가 있거나 없는 임산부를 대상으로 한 그룹 B 연쇄상구균 백신: 비무작위 2상, 공개 라벨, 다기관 시험Articles Published on 2016-05-012022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] (no infection adverse event Adverse reaction Analysis Antenatal antibody antibody concentration Antibody concentrations Birth Blood CD4 cell Cell clinics collected Concentration died disease dose enrolled event finding Fold change Follow-up funding geometric geometric mean gestation GlaxoSmithKline group groups HIV HIV infection HIV-uninfected immunogenic immunogenicity increased risk Infant Infants Infection intramuscularly invasive Italy less life maternal antibody Medical Research Council Meningeal mother multicentre Neonate Neonates no infection Novartis Open-label participant Pathogens Phase 2 placental pregnant women Primary outcome Primary outcomes Protective provided recruited reduce Registered reported respiratory resulting safety analyses serotype-specific serotypes serum serum sample Siena South Africa stillborn the vaccine three group three groups transfer transferred Trial trivalent unit vaccination Vaccine Wellcome Trust were measured with HIV women [DOI] 10.1016/S1473-3099(15)00484-3 PMC 바로가기 [Article Type] Articles